HCA Healthcare, Inc. (NYSE:HCA) Holdings Lifted by Mizuho Securities USA LLC

Mizuho Securities USA LLC lifted its holdings in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 205.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 45,637 shares of the company's stock after purchasing an additional 30,693 shares during the quarter. Mizuho Securities USA LLC's holdings in HCA Healthcare were worth $18,548,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of HCA. Vanguard Group Inc. grew its holdings in HCA Healthcare by 0.4% during the first quarter. Vanguard Group Inc. now owns 16,989,683 shares of the company's stock worth $5,666,569,000 after purchasing an additional 60,304 shares during the period. Capital World Investors lifted its position in shares of HCA Healthcare by 57.5% during the 1st quarter. Capital World Investors now owns 2,792,377 shares of the company's stock worth $931,342,000 after buying an additional 1,019,750 shares during the last quarter. Darsana Capital Partners LP boosted its stake in shares of HCA Healthcare by 53.3% during the second quarter. Darsana Capital Partners LP now owns 1,150,000 shares of the company's stock valued at $369,472,000 after purchasing an additional 400,000 shares in the last quarter. TD Asset Management Inc increased its holdings in HCA Healthcare by 2.7% in the second quarter. TD Asset Management Inc now owns 741,130 shares of the company's stock valued at $238,110,000 after purchasing an additional 19,812 shares during the period. Finally, Epoch Investment Partners Inc. boosted its stake in shares of HCA Healthcare by 16.4% in the 2nd quarter. Epoch Investment Partners Inc. now owns 631,854 shares of the company's stock valued at $203,002,000 after purchasing an additional 88,948 shares during the last quarter. Institutional investors own 62.73% of the company's stock.

Insider Activity

In other HCA Healthcare news, EVP Michael S. Cuffe sold 8,358 shares of the company's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the transaction, the executive vice president now directly owns 29,678 shares in the company, valued at approximately $11,438,494.76. This represents a 21.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Phillip G. Billington sold 3,897 shares of the company's stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the completion of the transaction, the senior vice president now owns 52,702 shares in the company, valued at approximately $18,445,700. This trade represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,155 shares of company stock valued at $5,608,990. 1.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on HCA shares. Royal Bank of Canada increased their target price on shares of HCA Healthcare from $378.00 to $405.00 and gave the stock an "outperform" rating in a research note on Friday, August 23rd. Truist Financial boosted their price target on shares of HCA Healthcare from $390.00 to $430.00 and gave the stock a "buy" rating in a report on Monday, August 19th. Leerink Partners lifted their target price on HCA Healthcare from $367.00 to $396.00 and gave the company an "outperform" rating in a report on Wednesday, July 24th. UBS Group raised their price target on HCA Healthcare from $405.00 to $438.00 and gave the company a "buy" rating in a research report on Wednesday, August 14th. Finally, StockNews.com lowered HCA Healthcare from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $385.00.

HCA Healthcare Price Performance

Shares of NYSE HCA traded down $2.55 during mid-day trading on Friday, reaching $342.96. The company's stock had a trading volume of 1,863,478 shares, compared to its average volume of 1,186,336. The stock has a market capitalization of $86.87 billion, a P/E ratio of 15.40, a P/E/G ratio of 1.34 and a beta of 1.68. The company has a debt-to-equity ratio of 48.71, a quick ratio of 1.00 and a current ratio of 1.12. The stock has a 50-day moving average of $385.11 and a two-hundred day moving average of $357.25. HCA Healthcare, Inc. has a 1-year low of $238.82 and a 1-year high of $417.14.

HCA Healthcare Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be given a dividend of $0.66 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.77%. HCA Healthcare's payout ratio is currently 11.85%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.